DEF 14A: Neumora Therapeutics Sets Date for 2024 Annual Stockholders Meeting

Neumora Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as the independent auditor.

Summary

• Neumora Therapeutics will hold its Annual Meeting of Stockholders virtually on June 13, 2024, at 8:30 a.m. Eastern Time.
• Stockholders of record as of April 15, 2024, are eligible to vote.
• The meeting will address the election of two Class I directors with terms expiring in 2027 and the ratification of Ernst & Young LLP as the company's independent auditor for the year ending December 31, 2024.
• The Board of Directors recommends voting FOR the election of director nominees and FOR the ratification of the auditor appointment.
• The company's common stock outstanding as of the record date was 159,452,584 shares.
• The proxy statement and annual report on Form 10-K for the fiscal year ended December 31, 2023, are available online.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The recommendations are clear and the information is presented in a straightforward manner. The sentiment is slightly positive due to the routine nature of the announcements and the company's adherence to corporate governance best practices.

Positives

• The company is following good corporate governance practices by seeking stockholder ratification of the auditor appointment.
• The company provides multiple convenient methods for stockholders to vote, including online, by phone, and by mail.
• The company has a Code of Business Conduct and Ethics that applies to its officers, directors, and employees.
• The company has a Compensation Recovery (Clawback) Policy in place.

Risks

• Failure to ratify the selection of Ernst & Young LLP could require the Audit Committee to reconsider its choice of independent auditor.
• The company is an emerging growth company and has elected to comply with certain reduced public company reporting requirements, which may make it more difficult for investors to evaluate the company's performance.

Future Outlook

The Board intends to present the matters described in the proxy statement at the Annual Meeting and is unaware of any matters to be presented by other parties.

Management Comments

• The Board of Directors recommends that you vote FOR the election of the director nominees named in Proposal No. 1 of the Proxy Statement; and FOR the ratification of the appointment of Ernst & Young LLP, as the independent registered public accounting firm and independent auditor, as described in Proposal No. 2 of the Proxy Statement.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to vote on key decisions and hold the board accountable.

Comparison to Industry Standards

• The director compensation program is generally in line with industry standards for similarly sized biopharmaceutical companies.
• The company's corporate governance practices, such as having a Code of Business Conduct and Ethics and a Clawback Policy, are consistent with best practices for publicly traded companies.
• The audit and tax fees paid to Ernst & Young LLP appear reasonable compared to other companies in the biopharmaceutical industry.

Related Party Transactions

• In December 2023, Neumora issued 6,072,445 shares of common stock and paid $2.3 million in cash to former equity holders of BlackThorn Therapeutics, including entities affiliated with ARCH Venture Partners and directors Paul L. Berns and Matthew Fust, in satisfaction of a Phase 3 navacaprant milestone.
• Amgen Inc., a greater than 5% stockholder, is party to two license agreements and a research and collaboration agreement with Neumora.
• Neumora made payments to Amgen of $21.9 million and $25.0 million in 2023 and 2022, respectively, under the Amgen Collaboration Agreement.

Stakeholder Impact

• Shareholders have the opportunity to vote on key decisions, influencing the direction and oversight of the company.
• Employees are subject to the Code of Business Conduct and Ethics, promoting ethical behavior within the organization.
• The company's financial performance and corporate governance practices can impact its relationships with customers, suppliers, and creditors.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 13, 2024.
• The company will announce the voting results within four business days after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Ernst & Young, Auditor, Corporate Governance, Neumora Therapeutics